Stifel upgrades ‘oversold’ Rollins to Buy following pullback

As previously reported, Stifel analyst Michael Hoffman upgraded Rollins (ROL) to Buy from Hold with an unchanged price target of $40. Rollins shares declined by over 8% following a Q3 operational update yesterday from peer Rentokil (RTO), but the firm believes Rentokil’s slower than expected organic growth in North America may be “more company specific” and views Rollins shares as being “oversold” on the near-term organic growth fears, the analyst tells investors.